Emerging Trends Influencing The Growth Of The Desmoid Tumors Market: Increasing Focus On Drug Developments To Drive The Revenues

The Desmoid Tumors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Desmoid Tumors Market Size Expected to Be by 2034?
In the past few years, the desmoid tumors market has witnessed robust growth. It is projected to escalate from $2.97 billion in 2024 to $3.18 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. This growth during the historic period is credited to progress in medical imaging, genetic studies and knowledge, surgical advancements, increased awareness and education, and patient advocacy.

Expectations are high for robust growth in the desmoid tumors market size in the forthcoming years. The market is projected to escalate to a whopping $4.13 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%. This anticipated growth during the forecast period can primarily be credited to the advent of targeted therapies, precision medicine, wider global collaborations, approvals of novel therapies by regulatory bodies, and a more patient-centric approach. Key trends anticipated during the forecast period comprise advancements in therapy methodologies, precision medicine, detection of biomarkers, clinical trials and research programs, multidisciplinary treatment teams along with a strong emphasis on patient advocacy and support.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13228

What Are the Emerging Segments Within the Desmoid Tumors Market?
The desmoid tumors market covered in this report is segmented -

1) By Treatment: Surgery, Radiation Therapy, Anti-Inflammatory Medication, Hormone Therapy, Chemotherapy, Novel Molecular-Targeted Therapy, Other Treatments
2) By Diagnosis: Biopsy, Electron Microscopic Examination, Immunohistochemical Analysis, Other Diagnosis
3) By End-User: Hospitals And Clinics, Specialty Centers, Other End-Users

Subsegments:
1) By Surgery: Wide Excision, Minimally Invasive Surgery
2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy
3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids
4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors
5) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy
6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Therapies
7) By Other Treatments: Watchful Waiting, Physical Therapy, Pain Management Strategies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp

What Long-Term Drivers Are Shaping Desmoid Tumors Market Trends?
The surge in cancer incidences is anticipated to spur the expansion of the desmoid tumor market. Cancer represents a group of diseases marked by abnormal cell growth and divisiveness, which can negatively affect nearby tissues and organs. The global increase in cancer incidences has increased the need for advanced and effective chemotherapeutic agents, thus positively impacting the desmoid tumor market. For example, The National Cancer Institute, a US Federal government agency, projected in May 2024 that there would be an estimated 2,001,140 new cancer cases in the U.S., leading to 611,720 anticipated deaths from the disease in that year. In 2022, nearly 20 million new cases were reported globaly, along with 9.7 million cancer-related fatalities. By 2040, the annual rate of new cancer cases is predicted to climb up to 29.9 million, with cancer-related deaths reaching 15.3 million. Hence, the growth of the desmoid tumor market is being fuelled by the increasing instances of cancer. The desmoid tumor market is expected to be driven by escalating government funding for research and development. This refers to the financial support provided by the government for specific objectives. Key to advancing cancer research and treatment, government funding facilitates scientific investigation, enhances medical infrastructure, and improves access to care, ultimately enhancing cancer diagnosis, prevention, and patient outcomes. In September 2023, for example, the National Cancer Institute, a US government agency, obtained a $7.3 billion budget from the US Congress for the Cancer Moonshot for fiscal year 2023, marking a $408 million increase from 2022. Therefore, the growth of the desmoid tumor market is propelled by the growing government funding for research and development.

Who Are the Top Competitors in Key Desmoid Tumors Market Segments?
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

What Desmoid Tumors Market Trends Are Gaining Traction Across Different Segments?
Leading entities in the desmoid tumors market are focusing on the creation of innovative medications like nirogacestat to cater more effectively to their current consumer base. Nirogacestat, a gamma-secretase inhibitor, is a small-molecule oral drug. For example, in February 2023, the US clinical-stage biopharmaceutical firm, SpringWorks Therapeutics Inc., announced that their new drug application (NDA) for nirogacestat for the treatment of adult desmoid tumors had been accepted and given priority review by the U.S. Food and Drug Administration (FDA). It is hypothesized that nirogacestat functions by inhibiting the creation of notch proteins, leading to tumor cell death. Desmoid tumors are known to generate a large amount of notch protein, which is believed to play a role in their development. Additionally, nirogacestat offers a novel therapy alternative that could potentially enhance patient outcomes.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Which Regions Are Becoming Hubs for Desmoid Tumors Market Innovation?
North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Desmoid Tumors Market?
2. What is the CAGR expected in the Desmoid Tumors Market?
3. What Are the Key Innovations Transforming the Desmoid Tumors Industry?
4. Which Region Is Leading the Desmoid Tumors Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.